『Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial』（Lancet Oncol 2020;21:655）より まとめ 無症候性脳転移に対するぺムブロリ…